AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03993301 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular formula
Description: Feeding baby two meals a day with regular formula at least.
Study NCT01738074 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent rotavirus genetic reassortment vaccine
Study NCT01738074 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03651128 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121
Study NCT03651128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab
Study NCT03651128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide
Study NCT03651128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT03651128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib
Study NCT03651128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib
Study NCT03651128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide
Study NCT03651128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib
Study NCT03651128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Elotuzumab
Study NCT03727386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: Participants will receive 30 ml of virgin coconut oil to replace their normal oil intake for a period of 6 months.
Study NCT03727386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil
Description: Participants will receive 30 ml of sunflower oil to replace their normal oil intake for a period of 6 months.
Study NCT01001143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study NCT05435131 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serum obtaining
Description: Serum obtaining : 8 ml of venous blood was collected from each participant and collecting blood centrifuged to obtain serum
Study NCT03830567 — intervention group
Intervention type: OTHER
Intervention: Pharmacist prescription
Description: Pharmacist prescribed hormonal contraception (initiation or continuation).
Study NCT00080314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
Study NCT00080314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, Once daily, 8 weeks.
Study NCT03143426 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D laparoscopic cholecystectomy
Description: Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
Study NCT03489109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: Subject will consume approximately 25% of their daily calories for 2 days per week. The other 5 days they will eat their normal diet
Study NCT03830567 — intervention group
Intervention type: OTHER
Intervention: Clinician prescription
Description: Clinician prescribed hormonal contraception (initiation or continuation).
Study NCT03489109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subject will receive standard of care recommendations for healthy diet and lifestyle
Study NCT02910063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Blinatumomab monotherapy
Study NCT04053049 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Meals composed of either high fat vs. high carbohydrate and semi-solid vs. solid
Study NCT01421667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 1.8 mg/kg every 3 weeks by IV infusion
Study NCT01421667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 every 3 weeks by IV infusion
Study NCT01001143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene
Study NCT02111070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-YANG FLU Vaccine
Description: 0.5mL
Study NCT01536938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100
Study NCT01536938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipotriol
Study NCT01536938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Study NCT05469880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: moisturizing cream and 5% benzoyl peroxide gel
Description: Group A: Eclaran 5% every evening and formula 609567 49 every morning, for 3 months.~Then the group is divided: Group A1/ formula 609613 37 and Group A2/ formula 609567 49 every morning, for the next 3 months
Study NCT05469880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: anti-acne face cream and 5% benzoyl peroxide gel
Description: Group B: Eclaran 5% every other night and 609613 37 every morning, for 3 months.~Then the group is divided: Group B1/ 609613 37 and Group B2/ formula 609567 49 every morning, for the next 3 months
Study NCT00402285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lycopene supplement
Study NCT00402285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil supplement
Study NCT00402285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebos for lycopene and fish oil.
Study NCT01377324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol
Description: A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with \~200MBq 18F-FES
Study NCT01641341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis
Description: once a day for seven to eight weeks
Study NCT01641341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pancrelipase
Description: Pancrelipase (one capsule prior to meals or snacks)
Study NCT01641341 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide (500mg twice a day for 7 days)
Study NCT02617628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: extended release naltrexone
Description: Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
Study NCT04274842 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: observation by D-OCT
Description: observation by D-OCT before, after, 1-3 days after, and 1 month after IPL treatment
Study NCT00935753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sapropterin
Description: oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
Study NCT04834076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA
Description: ELISA is is a test that detects and measures toxoplasma IgG and IgM antibodies in blood.
Study NCT01641341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule will not contain active treatment ingredients.
Study NCT01487694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cimicifuga racemosa
Description: Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
Study NCT01487694 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo without active ingredient 1 tab daily for 12 weeks
Study NCT00612378 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GFX System
Description: The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
Study NCT00503906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Study NCT00503906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00503906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Study NCT05080413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser shoes
Description: Path Finder® is a device that is fixed to the noses of the patient's shoes using a rubber strap, and laser-marks the place to be stepped on the ground of the opposite foot when walking. It is installed on both feet to relieve the symptoms of freezing of gait.
Study NCT02131090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tegaderm TM
Description: This is a generic adhesive dressing which is commonly used to secure epidural catheters.
Study NCT02131090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lock-it Plus
Description: This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
Study NCT02131090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epifix
Description: This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
Study NCT04254653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Indian and Alaska Native What Can I Eat?
Description: Participants will engage in 5 \~90 minute diabetes nutrition education classes. They will learn about healthy eating for type 2 diabetes management. Classes include didactic lesson, hands on learning activity, sharing session, mindful nutrition practice, and physical activity
Study NCT01761942 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fatty acids preparation- eye-q
Description: 3x2 tablets daily by 70 days
Study NCT04105595 — intervention group
Intervention type: DEVICE
Intervention: Septal defect closure
Description: Device closure of atrial septal defect
Study NCT05080413 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metronome
Description: The metronome, which makes a sound with a constant beat, is known to have an effect on the symptoms of Freezing of Gait in Parkinson's disease patients. At a rate of 80 beats per minute, the volume of sound that the patient can fully recognize is set to resolve the freezing of gait using the metronome sound.
Study NCT00864123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
Study NCT03638050 — intervention group
Intervention type: OTHER
Intervention: Functional Capacity Assessment
Description: Individuals will be assessed on the third day after acute myocardial infarction. The six-minute walk test will be performed according to the norms of the American Thoracic Society.
Study NCT02752633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopurinol
Description: This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
Study NCT02752633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat
Description: This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
Study NCT02583633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal nitroglycerin
Study NCT02583633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nifedipine
Study NCT04560816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).
Study NCT00864123 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral therapy
Description: All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
Study NCT00864123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-cycloserine
Description: D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
Study NCT00864123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
Study NCT04834076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Polymerase chain reaction (PCR) is a method widely used to rapidly make millions to billions of copies of a specific DNA sample, allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
Study NCT04834076 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sequencing
Description: DNA sequencing is a laboratory technique used to determine the exact sequence of bases (A, C, G, and T) in a DNA molecule. The DNA base sequence carries the information a cell needs to assemble protein and RNA molecules. DNA sequence information is important to scientists investigating the functions of genes.
Study NCT04560816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT04614740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC004
Description: 25 mg capsules,50 mg capsules,100 mg capsules.
Study NCT00959309 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strategies to decrease screen time in children
Description: 15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.~Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
Study NCT00959309 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Strategical Media Education
Description: Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
Study NCT04361721 — intervention group
Intervention type: DRUG
Intervention: Erenumab
Description: First injection of erenumab 70 mg subcutaneously was administered in hospital. The second injection of erenumab 70 mg was administered in hospital after 28 days, while the third and last dose of erenumab 70 mg was self-administered at home by the patients themselves after an additional 28-day interval.
Study NCT00422968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Description: Using silorimus eluting stent
Study NCT00422968 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronary artery bypass graft
Description: coronary artery bypass graft
Study NCT04570982 — intervention group
Intervention type: BIOLOGICAL
Intervention: Convalescent Plasma
Description: The objective of this protocol is to provide a coordinated approach for distribution and guidance for safe and effective administration of convalescent serum with antibodies against SAR CoV-2 for treatment of patients with COVID-19 infection who are most likely to benefit from this investigational treatment and monitor them.
Study NCT04071639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol 2Mg Tab
Description: Haloperidol take 0.5mg\~2mg three time a day.
Study NCT04071639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone 1Mg Tab
Description: Risperidone take 1mg once at night.
Study NCT04071639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoloft 50Mg Tablet
Description: Zoloft take 50mg once in the morning.
Study NCT04560816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin (400 milligrams) will be administered orally.
Study NCT02731820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium citrate
Description: Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Study NCT02731820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
Study NCT02731820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 400 IU/die Vitamin D3 daily by mouth
Study NCT04071639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Idebebone take 30mg three times a day.
Study NCT04071639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine Oral Tablet [Austedo]
Description: The recommended starting dose of Austedo is 6 mg administered orally once daily, and dose may be increased at weekly intervals in increments of 6 mg per day to a maximum recommended daily dosage of 48 mg.
Study NCT03551704 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT + EFT
Description: The CBT treatment will be implemented in 8-week group-based sessions (maximum 4 patients). Sessions will be carried out once a week over an 8-week period, with quit date occurring at fifth session. Patients will be asked to gradually reduce their nicotine intake (i.e., 25% each week). CBT components include: psychoeducation, self-monitoring, physiological feedback, training in stimulus control and strategies for controlling negative discomfort, and relapse prevention strategies.~As part of the EFT, participants will be asked to select future smoking-related events that would occur within the following time periods: 2 weeks, 1, and 6 months. They will be instructed to generate personal audio recordings that will be used to help them think about future decision-making choices.
Study NCT03551704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT + EFT + CM
Description: This intervention includes the abovementioned treatment components and a CM procedure reinforcing abstinence. This arm will consist on delivering CBT and EFT and providing patients incentives to promote and reinforce abstinence contingent on abstinence. The schedule will incorporate an increasing magnitude of reinforcement.
Study NCT01974440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: 90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
Study NCT01974440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 90 milligram per meter square (mg/m\^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
Study NCT01974440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.
Study NCT01974440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered intravenously on Day 1 of Cycles 1 to 6.